Neuromyelitis Optica (NMO) in Children: A Rare Case Report

*Dodik Tugasworo orcid scopus  -  Faculty of Medicine, Diponegoro University, Indonesia
Aditya Kurnianto orcid  -  Faculty of Medicine, Diponegoro University, Indonesia
Retnaningsih Retnaningsih orcid  -  Faculty of Medicine, Diponegoro University, Indonesia
Yovita Andhitara orcid  -  Faculty of Medicine, Diponegoro University, Indonesia
Rahmi Ardhini orcid  -  Faculty of Medicine, Diponegoro University, Indonesia
Tomy Nugroho  -  Faculty of Medicine, Diponegoro University, Indonesia
Jethro Budiman orcid  -  Faculty of Medicine, Diponegoro University, Indonesia
Received: 9 Jul 2020; Revised: 31 Oct 2020; Accepted: 24 Nov 2020; Published: 31 Dec 2020; Available online: 31 Dec 2020.
DOI: https://doi.org/10.14710/jbtr.v6i3.8451 View
Cover Letter
Subject
Type Research Instrument
  Download (21KB)    Indexing metadata
Copyright
Subject
Type Other
  Download (455KB)    Indexing metadata
Open Access
Citation Format:
Abstract

Background: Neuromyelitis optica (NMO) is a rare autoimmune disease that covers 20-30% of diseases related to autoimmune disorders and about 1% of demyelination diseases. NMO symptoms are vary between individuals, there are generally 2 main symptoms, transverse myelitis and optic neuritis. This article reported a child with NMO disease based on The Consensus of the International Panel for NMO Diagnosis (IPND) 2015.

Case Presentation: An 8-year old boy with spastic tetraparesis, bilateral nervus opticus dysfunction, urinary retention, and allodynia et causa suspected NMO. Patient received therapy using high-dose intravenous methylprednisolone and showing a clinical improvement.

Conclusion: This patient was diagnosed NMO based on IPND 2015 with an unknown AQP4-Ab status accompanied by supporting clinical symptoms. The management of NMO with high-dose intravenous methylprednisolone in this patient provides a meaningful response to the clinical improvement of the disease.

 

Note: This article has supplementary file(s).

Keywords: neuromyelitis optica; autoimmune; methylprednisolone

Article Metrics:

  1. Huda S, Whittam D, Bhojak M, Chamberlain J, Noonan C, Jacob A, et al. Neuromyelitis optica spectrum disorders. Clin Med. 2019; 19(2):169-176
  2. Kim WB, Lee SY, Kim BR, Kim YJ. Rehabilitation of neuromyelitis optica. Medicine. 2019; 98(41):1-5
  3. Lana-Peixoto MA, Talim N. Neuromyelitis Optica Spectrum Disorder and Anti-MOG Syndromes. Biomedicines. 2019;7(2):1-24
  4. Bertado CB, Martinez CCE, Martinez MM. Devic’s disease: A case report and literature review. Rev Fac Med UNAM. 2018;61(1):26-32
  5. Chi LM, Gao Y, Nan G. A case report of neuromyelitis optica spectrum disorder with peripheral neuropathy as the first episode. Medicine. 2018; 97(10):1-3
  6. Medina RR, Sanchez JA, Bertado CB, Martinez CCE, Martinez MM. Devic’s disease: A case report and literature review. Rev Fac Med UNAM. 2018;61(1):26-32
  7. Waheed S, Hussian J, Saood Y, Shehzadi A. Neuromyelitis Optica (NMO): A Case Report. PJNS. 2018; 13(3): 21-26
  8. Badri N, Teleb M, Syed S, Wardi M, Porres-Agular M, Cruz-Flores S. Seronegative Neuromyelitis Optica: A Case Report of a Hispanic Male. Case Rep Neurol. 2016; 8:102-107
  9. Gurgen N, Yalcin D, Gozukizil ST, Polisci D. Neuromyelitis Optica: Case Report. SETB. 2016; 50(2): 166-170
  10. Sepulveda M, Armangue T, Sola-Valls N, Arrambide G, Meca-Lallana JE, Oeeja-Guevara C, et al. Neuromyelitis Optica Spectrum Disorders: Comparison According to the Phenotype and Serostatus. Neurol Neuroimmunol Neuroinflamm. 2016;3(3):1-11
  11. Sudulagunta SR, Sodalagunta MB, Khorram H, Sepehrar M and Noroozpour Z. Neuromyelitis optica (NMO). SM J Clin Med Imaging. 2015; 1(1): 1-5
  12. Pereira WLDC, Reiche EMV, Kallaur AP, Maciel DRK. Epidemiological, clinical, and immunological characteristics of neuromyelitis optica: A review. J Neurol Sci. 2015; 355(1-2): 7-17
  13. Huang TL, Lin KH, Wang JK, Tsai RK. Treatment strategies for neuromyelitis optica. Tzu Chi Med J. 2018; 30(4): 204-208
  14. Weinshenker BG, Wingerchuk DM. Neuromyelitis Spectrum Disorders. Mayo Clin Proc. 2017; 92(4): 663-679
  15. Pandit L, Asgari N, Apiwattanakul M, Palace J, Paul F, Leite MI, et al. Demographic and clinical features of neuromyelitis optica; A review. Mult Scler. 2015;21(7):845-853
  16. Ochi H, Fujihara K. Demyelinating diseases in Asia. Curr Opin Neurol. 2016;29(3):222-228
  17. Tapiheru LA, Sinurat PPO, Ritarwan K. Myelitis transversa. JMS. 2007; 40(3): 230-236
  18. Hoorbakht H, Bagherkashi F. Optic Neuritis, its Differential Diagnosis and Management. Open Ophthalmol J. 2012; 6: 65-72
  19. Menon V, Saxena R, Misra R, Phuljhele W.Management of optic neuritis. Indian J Ophthalmol. 2011; 59: 117-122
  20. Wilhelm H, Schabet M: The diagnosis and treatment of optic neuritis. Dtsch Arztebl Int. 2015; 112: 616-626
  21. Hidayat M. Clinical Profile of Bilateral Optic Neuritis. JKA. 2018; 7 (Supplement 1): 17-23
  22. Cree B.C. Handbook of Clinical Neurology. Netherland: Elsevier; 2014
  23. Aninditha T, Wiratman W. Buku Ajar Departemen Neurologi. Jakarta: Penerbit Kedokteran Indonesia; 2017
  24. Dutra BG, Rocha AJD, Nunes RH, Junior ACMM. Neuromyelitis Optica Spectrum Disorders: Spectrum of MR Imaging Findings and Their Differential Diagnosis. Radiographics. 2018;38(1):169-193
  25. Wingerchuk DM, Banwell B, Bennett JL. Cabre P, Carroll W, Chitnis T. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189

Last update: 2021-04-18 01:17:54

No citation recorded.

Last update: 2021-04-18 01:17:56

No citation recorded.